Close Menu

NEW YORK (GenomeWeb) – Genomic Health reported today that its fourth quarter revenues rose 6 percent year over year, with sharper growth in international sales and prostate cancer testing than in the company's core US breast cancer market.

For the three months ended Dec. 31, 2017, Genomic Health's total revenues were $87.5 million compared to $82.7 million in the same period last year, missing the consensus Wall Street estimate of $88.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.